Publications by authors named "Paul Bycott"

Claim this Profile
C
Current usage and challenges of master protocols-based on survey results by ASA BIOP oncology methodology working group master protocol sub-team.
Xiaoyun Li, Chengxing Lu, Kristine Broglio, Paul Bycott, Jie Chen

Ann Transl Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials.
Chengxing Cindy Lu, Xiaoyun Nicole Li, Kristine Broglio, Paul Bycott, Qi Jiang

Ther Innov Regul Sci· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.
Bo Huang, Paul Bycott, Enayet Talukder

J Biopharm Stat· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.
Tatsuya Ioka, Takuji Okusaka, Shinichi Ohkawa, Narikazu Boku, Akira Sawaki, Paul Bycott

Jpn J Clin Oncol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer.
Igor M Bondarenko, Antonella Ingrosso, Paul Bycott, Sinil Kim, Cristina L Cebotaru

BMC Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.
Yiyun Tang, Paul Bycott, Orjan Akerborg, Linus Jönsson, Sylvie Negrier

Cancer Manag Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
Laura D Locati, Lisa Licitra, Laura Agate, Sai-Hong I Ou, Andree Boucher, Paul Bycott

Cancer· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer.
Chandra P Belani, Nobuyuki Yamamoto, Igor M Bondarenko, Artem Poltoratskiy, Silvia Novello, Paul Bycott

BMC Cancer· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib.
Brian I Rini, Thibault de La Motte Rouge, Andrea L Harzstark, M Dror Michaelson, Glenn Liu, Paul Bycott

Clin Genitourin Cancer· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
Peter C Trask, Andrew G Bushmakin, Joseph C Cappelleri, Jamal Tarazi, Brad Rosbrook, Paul Bycott

J Cancer Surviv· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Hope S Rugo, Alison T Stopeck, Anil A Joy, Stephen Chan, Shailendra Verma, Paul Bycott

J Clin Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
Hedy L Kindler, Tatsuya Ioka, Dirk J Richel, Jaafar Bennouna, Richard Létourneau, Paul Bycott

Lancet Oncol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Joan H Schiller, Timothy Larson, S-H Ignatius Ou, Steven Limentani, Alan Sandler, Paul Bycott

J Clin Oncol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Ezra E W Cohen, Lee S Rosen, Everett E Vokes, Merrill S Kies, Arlene A Forastiere, Paul Bycott

J Clin Oncol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib.
Peter C Trask, Andrew G Bushmakin, Joseph C Cappelleri, Paul Bycott, Katherine Liau

Acta Oncol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.
Jean-Philippe Spano, Catherine Chodkiewicz, Joan Maurel, Ralph Wong, Harpreet Wasan, Paul Bycott

Lancet· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
Olivier Rixe, Ronald M Bukowski, M Dror Michaelson, George Wilding, Gary R Hudes, Paul Bycott

Lancet Oncol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, M Dror Michaelson, Ronald M Bukowski, Paul W Bycott

N Engl J Med· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Francis J Giles, William T Bellamy, Zeev Estrov, Susan M O'Brien, Srdan Verstovsek, Paul Bycott

Leuk Res· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.
John Nemunaitis, Irene Eiseman, Casey Cunningham, Neil Senzer, Adrienne Williams, Paul Bycott

Clin Cancer Res· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.
Oday Hamid, Mary L Varterasian, Scott Wadler, J Randolph Hecht, Al Benson, Paul Bycott

J Clin Oncol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis